but because bavi can be armed, it would constitute a new patent for future versions; kind of like the bavi imaging, no? I'm talking straight buy-out. Wouldn't that be considered by a potential buyer?
How about Neudexta? I'm thinking of getting back in eventually (30 day wash rule up soon).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.